Labeling Changes. Without admitting wrongdoing or liability and solely to avoid the cost and disruption of further litigation, Perrigo agrees that for a period of twenty four (24) months commencing nine (9) months after the Effective Date, Perrigo will (i) include the language “individual results may vary” on the labels of the Covered Products and/or any other Perrigo- manufactured glucosamine and/or chondroitin products offered for resale, and (ii) will remove references to “rebuilding,” “renewing” “regrowing,” “growing,” “adding” or “regenerating” cartilage on the labels of the Covered Products and any other Perrigo-manufactured glucosamine and/or chondroitin products offered for resale.
Labeling Changes. With respect to changes to the Printed Matter, the Parties shall cooperate in making such changes promptly and Allendale shall, unless otherwise agreed, reimburse NPI for all remaining obsolete stock of Products, all inventory of Printed Matter (at NPI actual acquisition cost plus 15%) and all remaining obsolete work in process of Products resulting from any such change or amendment to the Printed Matter. Allendale may, at any time during the Supply Term, change or amend any item of the labeling by notice hereunder, such change or amendment to be effective after appropriate advance written notice hereof.
Labeling Changes. Should Xxxxxxx request or be required to make any modifications to Product labeling and packaging, it shall submit a written change order to Pfizer containing the requested or required modifications, together with any documentation specifying the content of the new labeling and packaging, including all necessary photo-ready art (or its substantial equivalent). Pfizer shall promptly provide Xxxxxxx with a statement of estimated charges for the work to be performed based on its per/person, per/hour rates then in effect, and its estimated timeline for implementing the changes. Upon written approval by Xxxxxxx, which approval shall not be unreasonably withheld, Pfizer will perform all requested or required labeling and packaging work. Xxxxxxx shall pay Pfizer for the work performed, in addition to reimbursing Pfizer for the cost of any existing labeling and packaging that has become obsolete as a result of such changes; provided, however, that such labeling and packaging shall not exceed the quantity of labeling and packaging required for the Product forecasted by Xxxxxxx for manufacture in the relevant Firm Order Period.
Labeling Changes. With respect to changes to the Printed Matter, the Parties shall co‐operate in making such changes promptly and BevCanna shall, unless otherwise agreed, reimburse Naturo for all remaining obsolete stock of Finished Products, all inventory and Printed Matter (at Naturo actual acquisition cost) and all remaining obsolete work in process of Finished Products resulting from any such change or amendment to the Printed Matter. BevCanna may, at any time during the Term, change or amend any item of the labeling by notice hereunder, such change or amendment to be effective after appropriate advance written notice hereof.
Labeling Changes a. Without admitting liability and solely to avoid the cost and disruption of further litigation, Defendant, as defined in the release set forth in this Agreement, agrees that, commencing after the Effective Final Judgment Date, it will not make the following statements, or statements conveying the same messages, on Direct Digital’s packaging and labeling, or in promotional materials under Direct Digital’s direct control, on product internet websites under Direct Digital’s direct control, or in any other advertising media under Direct Digital’s direct control, pertaining to the formulation of Instaflex, or any other identical or substantially similar joint health benefit product Direct Digital manufactures or offers for sale under any different product name: (i) that any such product provides joint support;
Labeling Changes. Allergan may, in its sole discretion, make changes to labels, product inserts and other Labeling for a specific Product, for which changes Allergan shall obtain approval of all applicable Regulatory Authorities responsible for the approval of a specific Product, as required.
Labeling Changes. Should Omeros request or be required to make any modifications to Product labeling and packaging, it shall submit a written change order to Hospira containing the requested or required modifications, together with any documentation specifying the content of the new labeling and packaging, including all necessary photo-ready art (or its substantial equivalent). Hospira shall promptly provide Omeros with a statement of charges for the work to be performed based on its per/hour, per/person rates then in effect and its estimated timeline for implementing the changes. Upon written approval by Omeros, which approval shall be at Omeros’ sole discretion, Hospira shall perform such requested or required labeling and packaging work. Omeros shall pay Hospira for the work performed, in addition to reimbursing Hospira for the reasonable cost of any existing labeling and packaging that has become obsolete as a result of such changes.
Labeling Changes. Should AMAG request or be required to make any modifications to Product labeling and packaging, it shall submit a written change order to Pfizer containing the requested or required modifications, together with any documentation specifying the content of the new labeling and packaging, including all necessary photo-ready art (or its substantial equivalent). Pfizer shall promptly provide AMAG with a statement of charges for the work to be performed, reflecting professional service fees quoted at a rate of […***…] and its estimated timeline for implementing the changes. Upon written approval by AMAG, which approval shall not be unreasonably withheld, Pfizer will perform all requested or required labeling and packaging work. AMAG shall pay Pfizer for the work performed, in addition to reimbursing Pfizer for the cost of any existing labeling and packaging that has become obsolete as a result of such changes; provided, however, that obsolescence charges do not exceed the amount of labels reasonably required by Technical Transfer & Supply Agreement (signature version) CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[…***…]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24B-2 PROMULGATED UNDER THE SECURITIES ACT OF 1934, AS AMENDED. Pfizer based on the first […***…] of the most recent […***…] rolling forecast provided under Section 6.2 or such other amount as mutually agreed upon in writing.
Labeling Changes. Upon reasonable prior written notice to Manufacturer, Customer may, in its sole discretion, make changes to labels, product inserts and other SC1:4529841.10 [****] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. Confidential treatment has been requested with respect to the omitted portions. Labeling for the Product, which changes shall be submitted by Customer to all applicable Regulatory Authorities responsible for the approval of the Product, if required.
Labeling Changes. In the event either Party seeks to change a label and/or package insert for a Special Product due to safety or efficacy concerns, the Party seeking to make the change shall notify the other Party and provide the other Party with applicable data for its review and evaluation. The Parties may discuss in good faith and endeavor to agree upon all proposed significant safety or efficacy changes to the labeling and/or package inserts for Special Products. Each Party agrees to consider all comments of the other in good faith. Notwithstanding any good faith discussions, Abbott shall have the right to file for such labeling change as it reasonably deems appropriate in the Abbott Territory and AbbVie shall have the right to file for such labeling change as it reasonably deems appropriate in the AbbVie Territory, as applicable.